Prodromal Schizophrenia Clinical Trial
Official title:
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.
Several lines of evidence suggest that NMDA hypotheses have been implicated in schizophrenia. Previous studies found that some NMDA-enhancing agents were able to benefit the treatment of schizophrenia. Whether an NMDA-enhancer (NMDAE) can benefit the treatment of prodromal schizophrenia deserves study. Therefore, this study aims to compare NMDAE and placebo in the treatment of prodromal schizophrenia. The subjects with prodromal schizophrenia at first receive 6 weeks of health-promotion intervention (including exercise and education). A total of 48 subjects who do not respond sufficiently to the health-promotion program are then recruited to this 12-week, randomized, double-blind, placebo-controlled trial, which aims to compare treatment response of NMDAE vs. placebo in 1:1 ratio. Clinical performances and side effects are measured at weeks -6 (before the screening phase), 0 (baseline of the drug trial), 2, 4, 6, 9, and 12. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE and placebo will be compared. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03149107 -
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
|
Phase 3 | |
| Recruiting |
NCT05131035 -
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
|
N/A | |
| Completed |
NCT01269710 -
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
|
N/A | |
| Enrolling by invitation |
NCT05567848 -
Accelerated TMS in Psychosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03751865 -
Early Detection and Intervention for Women At-risk of Psychosis
|
N/A | |
| Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
| Completed |
NCT01597141 -
Psychosis: Early Detection, Intervention and Prevention
|
N/A | |
| Completed |
NCT00169988 -
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
|
N/A | |
| Completed |
NCT03447548 -
Neurofeedback Training for High Risk Psychosis
|
N/A | |
| Completed |
NCT06190483 -
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk
|
N/A | |
| Completed |
NCT01619319 -
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
|
N/A | |
| Recruiting |
NCT05167396 -
REtinal and VIsual Cortical Response in Early PSYchosis
|
N/A | |
| Terminated |
NCT00169949 -
Aripiprazole Treatment of the Prodrome
|
N/A | |
| Recruiting |
NCT04338152 -
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
|
N/A | |
| Recruiting |
NCT05142735 -
Effects of NAC on Symptoms of CHR Patients
|
N/A | |
| Enrolling by invitation |
NCT05532683 -
Feasibility Trial of a Lifestyle Intervention for CHR-P
|
N/A | |
| Enrolling by invitation |
NCT03970005 -
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
|